- Trial phase
- Not stated
- Time to market
- Not stated
- Why 2/10
- No hard, dated catalyst (PDUFA, pivotal readout, or IND) is identifiable for ACCG-3535 in the next ~12 months. The drug is not mentioned in any of Structure Therapeutics' recent SEC filings, press releases, or news coverage, suggesting it is a preclinical or very early-stage discovery candidate with no publicly announced clinical timeline.
ACCG-3535 does not appear in Structure Therapeutics' public pipeline disclosures. The company's focus is on aleniglipron (Phase 3 GLP-1 agonist) and ACCG-2671 (Phase 1/2a amylin receptor agonist). ACCG-3535 may be a discovery-stage or discontinued candidate. Investors should monitor Structure's pipeline page and quarterly filings for any mention of this compound before assigning it any value.
Price Chart
Executive Summary
ACCG-3535 is a development code assigned by Structure Therapeutics (NASDAQ: GPCR), a clinical-stage biopharmaceutical company focused on oral small-molecule therapies for obesity and metabolic diseases. However, extensive web research, SEC filing searches, and internal SecBot database queries found no public mention of ACCG-3535 in any press release, clinical trial registry, SEC filing, or news article. The company's known pipeline consists of aleniglipron (GSBR-1290, an oral GLP-1 receptor agonist in Phase 3), ACCG-2671 (an oral amylin receptor agonist in Phase 1/2a), and potentially other preclinical candidates. ACCG-3535 may be a discovery-stage or discontinued compound with no publicly available data.
The Two-Sided Case
Upcoming Catalysts
- No catalysts specific to ACCG-3535 can be identified. For the broader company, key catalysts include: three aleniglipron Phase 3 readouts expected in Q4 2026, and ACCG-2671 multiple ascending dose (MAD) data expected in the first half of 2027.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Structure Therapeutics Inc. PRESS-RELEASE GPCR ·Originating report